Category Archives: Other

Policy Analysis and Guidance: Shanghai Announces Second Supply and Incomplete Specification Enterprises for National Drug Procurement

Shanghai’s Medical Centralized Bidding and Procurement Affairs Management Office has released a notice announcing the determination of second supply and incomplete specification supply enterprises for the tenth batch of national centralized drug procurement. This initiative aims to ensure the stability of drug supply and adaptability to market dynamics, reflecting Shanghai’s commitment to optimizing its centralized procurement system.

Key Policy Highlights

  1. Second Supply and Incomplete Specification Enterprises
    • Purpose: To address market gaps and ensure uninterrupted drug supply.
    • Criteria: Determined based on market share and economic factors.
  2. Market Dynamics Adaptation
    • Flexibility: Provides flexibility in responding to market changes and supply chain disruptions.
  3. Attachment Details
    • Lists: Includes detailed lists of second supply and incomplete specification supply drugs for reference by relevant stakeholders.

Policy Orientation and Industry Implications
The announcement reflects Shanghai’s strategic focus on:

  • Supply Chain Resilience: Ensuring continuous drug availability through diversified supply sources.
  • Market Adaptability: Adapting procurement strategies to meet evolving market conditions.
  • Transparency: Enhancing clarity and accessibility of procurement information for stakeholders.

Conclusion
Shanghai’s approach to determining second supply and incomplete specification enterprises underscores its commitment to maintaining a stable and responsive pharmaceutical market. This policy supports the reliability of the centralized procurement system and ensures patient access to essential medications. Stakeholders should stay informed of these updates to maintain operational efficiency and compliance.-China Health Reform Pulse

Policy Source: https://www.smpaa.cn/xxgk/gggs/2025/03/26/16522.shtml

Policy Analysis and Guidance: China’s Centralized Drug Procurement Information Change Notification

China’s National Joint Procurement Office has issued a notification regarding the information change of selected drugs in the national centralized drug procurement. This notification allows for changes in drug marketing authorization holders, manufacturers, specifications, packaging, and enterprise names under certain conditions, while maintaining the selected status of the drugs. This move aims to enhance the flexibility and adaptability of the centralized procurement system, ensuring the continuity and stability of drug supply.

Key Policy Highlights

  1. Information Change Allowance
    • Conditions: Under specific conditions, changes in drug-related information are permitted without losing the selected status.
    • Purpose: To maintain the stability of the drug supply chain and adapt to market changes.
  2. Regulatory Compliance
    • Material Review: The change applications are subject to strict verification to ensure compliance with regulatory standards.
  3. Market Implications
    • Supply Stability: Ensures uninterrupted drug supply by allowing necessary information adjustments.
    • Industry Adaptability: Provides flexibility for enterprises to respond to market dynamics while maintaining their position in the procurement system.

Policy Orientation and Industry Implications
The notification reflects China’s strategic focus on:

  • Supply Chain Resilience: Prioritizing the stability and continuity of drug supply.
  • Regulatory Flexibility: Adapting regulatory measures to support industry dynamics and market changes.
  • Market Stability: Ensuring the centralized procurement system remains effective and responsive to industry needs.

Conclusion
China’s approach to allowing information changes in selected drugs under the centralized procurement system demonstrates a balance between regulatory rigor and industry flexibility. This policy supports the stability of the pharmaceutical market and ensures patient access to essential medications. Stakeholders should stay informed of these changes to maintain compliance and operational efficiency.-China Health Reform Pulse

Policy Source: https://www.smpaa.cn/gjsdcg/2025/03/26/16521.shtml

Policy Analysis and Guidance: Yunnan’s Routine Medical Consumables Delisting Notification

Yunnan Province’s Government Procurement and Tendering Center has issued a notification regarding the delisting of certain medical consumables under the routine listing work for batch 20250305. This move aims to optimize the market by removing products that no longer meet the listing criteria, ensuring quality and supply stability.

Key Policy Highlights

  1. Delisting Criteria
    • Basis: Products are delisted based on enterprise applications and supporting documentation.
    • Purpose: To maintain high standards for medical consumables and ensure market efficiency.
  2. Product Details
    • Example: The notification includes products like the “一次性使用麻醉呼吸管路组件” (Disposable Anesthesia Breathing Circuit Component) manufactured by Henan Tuoren Medical Device Group Co., Ltd.
  3. Contact Information
    • Support: Enterprises can contact the medical device procurement department for further inquiries.

Policy Orientation and Industry Implications
The delisting initiative reflects Yunnan’s strategic focus on:

  • Market Optimization: Removing underperforming or non-compliant products to enhance overall market quality.
  • Quality Assurance: Ensuring that only products meeting stringent standards remain available.
  • Transparency: Providing clear communication channels for enterprises regarding listing and delisting processes.

Conclusion
Yunnan’s approach to delisting medical consumables underscores its commitment to maintaining a high-quality and efficient market. This policy supports the reliability of the medical consumables supply chain and ensures healthcare providers have access to essential, quality-assured products. Enterprises should stay informed of these updates to maintain compliance and market access.-China Health Reform Pulse

Policy Source: http://www.ynyyzb.com.cn/detail.html?infoId=25153&CatalogId=3